| __timestamp | Agios Pharmaceuticals, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 100371000 | 60987000 |
| Thursday, January 1, 2015 | 141827000 | 125542000 |
| Friday, January 1, 2016 | 220163000 | 210460000 |
| Sunday, January 1, 2017 | 292681000 | 275119000 |
| Monday, January 1, 2018 | 1397000 | 409539000 |
| Tuesday, January 1, 2019 | 1317000 | 547758000 |
| Wednesday, January 1, 2020 | 2805000 | 736300000 |
| Friday, January 1, 2021 | 18777000 | 904200000 |
| Saturday, January 1, 2022 | 1704000 | 1080300000 |
| Sunday, January 1, 2023 | 9504000 | 1262200000 |
| Monday, January 1, 2024 | 4165000 | 1530500000 |
Unleashing the power of data
In the competitive world of biotechnology, understanding cost dynamics is crucial. Vertex Pharmaceuticals Incorporated and Agios Pharmaceuticals, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. Vertex Pharmaceuticals has seen a consistent rise, with costs increasing by over 1,900% from 2014 to 2023, peaking at approximately $1.26 billion in 2023. This reflects their aggressive expansion and investment in research and development.
Conversely, Agios Pharmaceuticals experienced a dramatic fluctuation, with costs peaking in 2017 and then dropping significantly. By 2023, their costs were around $9.5 million, a stark contrast to their 2017 peak. This volatility may indicate strategic shifts or changes in operational focus. These trends highlight the diverse strategies employed by biotech firms in managing their operational expenses over the past decade.
Cost of Revenue Comparison: Novo Nordisk A/S vs Vertex Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Novo Nordisk A/S and Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and ADMA Biologics, Inc.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Dyne Therapeutics, Inc.
Cost Insights: Breaking Down Viatris Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost of Revenue Comparison: Insmed Incorporated vs Agios Pharmaceuticals, Inc.
Cost of Revenue Trends: Catalent, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Evotec SE